PeriRx sanctioned over false negotiation claims in patent suit
24-01-2022
Bio-Rad and 10X Genomics end patent fight with new licensing deal
29-07-2021
Bayer and ERS enter CRISPR patent licensing agreement
19-05-2016
LifetimeStock / Shutterstock.com
Oral diagnostics company PeriRx has lost a patent licensing suit against the University of California and research company RNAmeTRIX, claiming that they had breached sublicensing agreements.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
PeriRx, US District Court for the Eastern District of Pennsylvania, big pharma, patent licensing
